Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MINISO Group Holding Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while MINISO Group Holding Ltd trades at $11.8 (market cap $3.52B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and MINISO Group Holding Ltd pays a 5.69% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MNSO | |
|---|---|---|
Market Cap | $4.49B | $3.52B |
Sector | Health | Technology |
52-Week High | $28.06 | $26.63 |
52-Week Low | $20.06 | $11.30 |
Enterprise Value | $3.69B | $4.19B |
Dividend Yield | — | 5.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MNSO trades at $11.90, up 1.54% today, with a bearish technical signal from moving averages and mixed oscillators. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth of 28.5% year-over-year, and announced a HK$2 billion share repurchase program on June 29, 2026. Valuation ratios appear reasonable with a P/E of 12.11 and P/S of 1.1, while profitability metrics show a net income margin of 8.98% and ROE of 18.88%.
The outlook is cautiously optimistic given earnings momentum and shareholder-friendly actions, but risks include margin pressure from rising expenses and competitive threats. Analyst sentiment is positive with 75% buy ratings, though technical indicators suggest near-term resistance. Investors should weigh solid fundamentals against bearish price trends for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
